is 8222 worth to buy and hold?

Please see the recent news about Ck Life Sciences and Wex Pharma in Canada, it shed the light of future of 8222.

VANCOUVER (CP) - Wex Pharmaceuticals Inc. (TSX:WXI) will raise $20 million in a financing deal with CK Life Sciences International that will give the Hong Kong company a 27 per cent stake in Wex.

Wex said Monday it will issue CK about 16.3 million shares at 27.5 cents per share for $4.49 million and convertible debentures worth $15.6 million.

Proceeds from the financing will be used to fund Phase 3 clinical trials of Wex's Tectin cancer pain treatment and for working capital purposes.

Under the agreement, Wex's board will be expanded with the additions of Alan Yu and Victor Tong as designated by CK.

The financing is subject to regulatory and shareholders approval.

Shares in Wex were untraded at 35 cents early Monday on the Toronto Stock Exchange

note: Wex stock price up 62 cent today.

Many people questioned who was Zhang Ling Yu, the chief scientist of CK Life since the company was publicly listed. But now we have an answer ... http://www.sanangroup.com/. This company's subsidiary is targeting the very very big safe food and cancer healing market.

The most valuable assets of the company are its patent, technology know-how and business/scientific talents. And I can see how strong the management team of the company is.

I can't believe the stock price will keep at the current level for too long. My personal forecast is very optimistic. It will not take much time for the price to reach $2 as I anticipate the half-year result coming in August will be unexpectedly well.

Another aspect supporting my optimistic expection on this company is the potential partnership with its sister company Wastons which has an extraordinary huge commercial network around the world. This gives the company an unbeatable advantage in distributing its products worldwide.